Google’s AI Found a Cancer Clue. Can Medicare Patients Benefit Yet?

Full body

The Medicare Insider Blog

By Jamie Sarno


By Jamie Sarno

    
    
    Read this article on LinkedIn to join the conversation
Read on LinkedIn
https://www.linkedin.com/comm/pulse/googles-ai-found-cancer-clue-can-medicare-patients-benefit-sarno-2wrne?lipi=urn%3Ali%3Apage%3Aemail_email_series_follow_newsletter_02%3Bh1um9BL4SW6npR9Ap2lZ%2FA%3D%3D&midToken=AQHr-yGO7Pl1Jw&midSig=3Q0-aIaToCmcw1&trk=eml-email_series_follow_newsletter_02-null-0-read_more_banner_cta_&trkEmail=eml-email_series_follow_newsletter_02-null-0-read_more_banner_cta_-null-6kau68~mwc7uvpp~6d-null-null&eid=6kau68-mwc7uvpp-6d
  
An AI prediction held up in laboratory tests. For patients, three questions remain: Does it work in people, who can access it, and who pays? A video circulating online carries a claim that would stop almost anyone facing cancer: Google has released a “cancer cure AI model.” The research behind the video deserves attention. So does the distance between that headline and a treatment someone can receive. On October 15, 2025, Google and Yale announced an AI model called Cell2Sentence-Scale 27B. Researchers used it to simulate the effects of more than 4,000 drugs and identify a potential way to make cancer cells more visible to the immune system. The model highlighted silmitasertib, an existing investigational drug also known as CX-4945. Laboratory experiments supported its prediction: combining the drug with low levels of interferon, an immune signaling protein, increased antigen presentation, the process through which cells display material the immune system can recognize. That finding gives researchers a promising lead. It does not establish that the combination shrinks tumors, extends lives or cures cancer in patients. For someone living with cancer, the distinction is personal. A discovery can be scientifically important long before it becomes a treatment option. The technology itself is worth understanding. Researchers trained the model using data from more than 50 million human and mouse cells, alongside biological text. It represents gene activity as “cell sentences” that a language model can analyze. The goal is to help scientists predict how cells respond to an intervention and choose useful experiments. The research paper describes validation in tumor fragments and separate human cell models. Those experiments help move a prediction beyond the computer. They still leave the clinical question unanswered: Will the approach safely help people? The PubMed record reviewed for this article identifies the paper as a preprint that has not yet been peer reviewed by a journal. There is another distinction that can get lost in a short video. Silmitasertib has already been tested in people. That does not mean the particular use identified by the AI has been proven in people. An earlier Phase 1b/2 study investigated the drug with chemotherapy for advanced bile duct cancer. Its authors reported preliminary evidence of benefit and side effects. That was a different treatment combination for a specific disease, not confirmation of the newer interferon finding. The National Cancer Institute also lists a Phase I/II study of silmitasertib with chemotherapy for relapsed or refractory solid tumors. A 2026 research abstract identifies its population as children and young adults. An older Medicare beneficiary should not read “clinical trials underway” as an invitation to enroll. The research has also attracted commercial interest. In March 2026, the drug’s developer, Senhwa Biosciences, announced a collaboration with CellType, a company founded by Yale researcher David van Dijk. The company’s disclosure described a pilot to explore the drug’s biology and potential treatment combinations. That is evidence of continued development. It is not evidence of a successful treatment. For Medicare readers, the practical story begins when an oncologist identifies an actual clinical trial that might fit the patient’s diagnosis, treatment history and health. Medicare can help pay for participation in qualifying research before a treatment becomes routine care. But the bills fall into different categories. CMS covers routine costs in qualifying clinical trials, subject to Medicare’s rules. It also covers reasonable and necessary care to diagnose and treat complications arising from participation in clinical trials. The experimental item or service itself is generally excluded under that policy unless it would otherwise be covered outside the trial. Services performed solely to collect research data are also excluded. Medicare does not pay for items the sponsor provides free. That means “Medicare covers the trial” is too broad an answer. Patients need to know which services will be billed to Medicare, which the sponsor will provide, and what they may owe. Deductibles and coinsurance can still apply. Medicare Advantage members can participate in qualifying studies, too. Medicare’s beneficiary guidance explains that certain covered trial services are paid through Original Medicare even when the patient belongs to an Advantage plan. The plan cannot prevent participation in a qualifying covered study, but patients should notify it and confirm how billing and cost sharing will work. For someone with Medigap, the same guidance says the policy pays its applicable benefits for Medicare covered routine trial costs as it would for other Medicare covered services. It generally does not turn an excluded experimental service into a covered benefit. Those details deserve attention before consent forms become appointments and appointments become bills. The questions to bring to the oncologist are straightforward. Is there a trial for my particular cancer? Does it test the approach described in the story? Am I eligible? What is already known about the risks and benefits? Who pays for the drug, routine care and any additional visits? As of November 8, 2026, I could not verify published human trial results demonstrating clinical benefit from the specific silmitasertib and interferon approach highlighted by Google and Yale. There is reason to follow this work. There is also reason to describe it accurately. The promise is that AI may help researchers find useful treatment ideas faster. The responsibility is to give patients a clear account of what has been tested, what remains uncertain and what they can actually access. For the person waiting for a better option, hope deserves more than a headline. It deserves evidence and a clear path to care. The Medicare Insider Question: When you read about a cancer breakthrough, what do you most want answered: how strong the evidence is, whether you can access it, or what your coverage will pay?
Keep reading on LinkedIn
https://www.linkedin.com/comm/pulse/googles-ai-found-cancer-clue-can-medicare-patients-benefit-sarno-2wrne?lipi=urn%3Ali%3Apage%3Aemail_email_series_follow_newsletter_02%3Bh1um9BL4SW6npR9Ap2lZ%2FA%3D%3D&midToken=AQHr-yGO7Pl1Jw&midSig=3Q0-aIaToCmcw1&trk=eml-email_series_follow_newsletter_02-newsletter_content_preview_text-0-readmore_button_&trkEmail=eml-email_series_follow_newsletter_02-newsletter_content_preview_text-0-readmore_button_-null-6kau68~mwc7uvpp~6d-null-null&eid=6kau68-mwc7uvpp-6d
  
      

----------------------------------------

This email was intended for Charles Punay (Head of Growth at Panel)
Learn why we included this: https://www.linkedin.com/help/linkedin/answer/4788?lang=en&lipi=urn%3Ali%3Apage%3Aemail_email_series_follow_newsletter_02%3Bh1um9BL4SW6npR9Ap2lZ%2FA%3D%3D&midToken=AQHr-yGO7Pl1Jw&midSig=3Q0-aIaToCmcw1&trk=eml-email_series_follow_newsletter_02-SecurityHelp-0-textfooterglimmer&trkEmail=eml-email_series_follow_newsletter_02-SecurityHelp-0-textfooterglimmer-null-6kau68~mwc7uvpp~6d-null-null&eid=6kau68-mwc7uvpp-6d
You are receiving LinkedIn notification emails. Others can see that you are a subscriber.


Unsubscribe: https://www.linkedin.com/series-notifications/?action=unsubscribe&memberToken=ADoAABeoI0AB3nZFGC87HBfpGXIbKukXbSQp8EA&newsletterId=7261751022514053120&newsletterTitle=The Medicare Insider Blog&lipi=urn%3Ali%3Apage%3Aemail_email_series_follow_newsletter_02%3Bh1um9BL4SW6npR9Ap2lZ%2FA%3D%3D&midToken=AQHr-yGO7Pl1Jw&midSig=3Q0-aIaToCmcw1&ek=email_series_follow_newsletter_02&e=6kau68-mwc7uvpp-6d&eid=6kau68-mwc7uvpp-6d&m=unsubscribe&ts=footerGlimmer&li=0&t=plh    ·  Help: https://www.linkedin.com/help/linkedin/answer/67?lang=en&lipi=urn%3Ali%3Apage%3Aemail_email_series_follow_newsletter_02%3Bh1um9BL4SW6npR9Ap2lZ%2FA%3D%3D&midToken=AQHr-yGO7Pl1Jw&midSig=3Q0-aIaToCmcw1&trk=eml-email_series_follow_newsletter_02-help-0-textfooterglimmer&trkEmail=eml-email_series_follow_newsletter_02-help-0-textfooterglimmer-null-6kau68~mwc7uvpp~6d-null-null&eid=6kau68-mwc7uvpp-6d

© 2026 LinkedIn Corporation, 1zwnj000 West Maude Avenue, Sunnyvale, CA 94085.
LinkedIn and the LinkedIn logo are registered trademarks of LinkedIn.